NASDAQ$AURA
Aura Biosciences Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Aura Biosciences reported financial results and business highlights for Q3 2024.
Aura Biosciences reported positive Phase 2 end-of-study data with Bel-sar in early-stage choroidal melanoma and the ongoing Phase 3 CoMpass trial recently received authorization to start enrolling patients in Europe. Multiple clinical complete responses were observed with a single low dose of Bel-sar in the ongoing Phase 1 trial in non-muscle invasive bladder cancer. The company's strong cash position is expected to support operations into 2H 2026.
- Presented positive Phase 2 end of study data with Bel-sar in early-stage choroidal melanoma.
- Received authorization to start enrolling patients in Europe in the ongoing Phase 3 CoMpass trial.
- Observed multiple clinical complete responses with a single low dose of Bel-sar in ongoing Phase 1 trial in Non-Muscle Invasive Bladder Cancer (NMIBC).
- Cash position is expected to support operations into 2H 2026.
Headline financials
Revenue & EPS history
Aura Biosciences · Revenue · Quarterly
$0
Forward guidance
Aura Biosciences believes its current cash and cash equivalents and marketable securities will fund operations into the second half of 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q3 2024
+1.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-7.0%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+26.0%
Q3 2021
Best reaction
-8.9%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.1% | -5.5% | -24.3% | |
| Q3 2025 | -0.7% | -2.9% | +17.4% | |
| Q2 2025 | +4.2% | -3.6% | -11.0% | |
| Q1 2025 | +1.9% | -0.5% | +6.8% | |
| Q4 2024 | -6.7% | -15.5% | -23.2% | |
| Q3 2024 | -7.3% | -15.0% | -24.2% | |
| Q1 2024 | -1.1% | +1.9% | +1.6% | |
| Q4 2023 | +2.9% | +1.7% | -5.4% | |
| Q3 2023 | +4.5% | +8.6% | +18.9% | |
| Q2 2023 | -8.9% | -8.8% | -16.4% | |
| Q1 2023 | +0.5% | +7.3% | +22.4% | |
| Q4 2022 | -1.0% | -1.0% | -15.6% | |
| Q3 2022 | +10.1% | +16.4% | +4.4% | |
| Q2 2022 | -0.5% | -2.6% | -19.0% | |
| Q1 2022 | +4.9% | +8.1% | -4.5% | |
| Q2 2021 | -1.5% | +8.7% | -21.4% | |
| Q4 2021 | -1.5% | +8.7% | -21.4% | |
| Q3 2021 | +26.0% | -1.1% | -10.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro